Response of nineteen cats with nasal lymphoma to radiation therapy and chemotherapy

Gabriella Sfiligoi, Alain P Theon, Michael S Kent

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The records of 19 cats treated for stage I nasal lymphoma with radiation therapy and chemotherapy were reviewed to determine response to therapy, treatment outcome and possible prognostic indicators. All cats were treated with megavoltage radiation therapy to a total dose ranging from 22 to 48 Gy (median dose=42 Gy). All cats were prescribed at least 6 months of multiagent chemotherapy. The median progression-free interval for all cats was 945 days (31 months). Two cats did not achieve clinical remission. Of 17 cats evaluable for relapse, 10 (58.8?) were progression free during the entire follow-up period. Four cats (23.5?) suffered local recurrence, while three (17.6?) experienced distant relapse. The median survival time was 955 days (31.4 months). The only variable found to have a significant negative impact on survival was destruction of the cribriform plate before therapy (P=0.002). The long progression free and survival times reported here indicate that cats with stage I nasal lymphoma treated with aggressive local and systemic therapy can have a favorable outcome when compared with other anatomic forms of lymphoma. Despite strong clinical responses to the multimodality therapy used, the fact that three (17.6?) cats relapsed distantly supports the recommendation that treatment with radiation therapy alone is insufficient until further prospective studies can be performed.

Original languageEnglish (US)
Pages (from-to)388-393
Number of pages6
JournalVeterinary Radiology and Ultrasound
Volume48
Issue number4
DOIs
StatePublished - Jul 2007

Fingerprint

radiotherapy
lymphoma
Nose
drug therapy
Lymphoma
Cats
Radiotherapy
cats
Drug Therapy
therapeutics
relapse
Recurrence
Ethmoid Bone
Therapeutics
remission
dosage
prospective studies
Disease-Free Survival
Prospective Studies

Keywords

  • Feline
  • Nasal lymphosarcoma
  • Treatment

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Response of nineteen cats with nasal lymphoma to radiation therapy and chemotherapy. / Sfiligoi, Gabriella; Theon, Alain P; Kent, Michael S.

In: Veterinary Radiology and Ultrasound, Vol. 48, No. 4, 07.2007, p. 388-393.

Research output: Contribution to journalArticle

@article{e2b13cb079154d13b98a282cbf68d4b3,
title = "Response of nineteen cats with nasal lymphoma to radiation therapy and chemotherapy",
abstract = "The records of 19 cats treated for stage I nasal lymphoma with radiation therapy and chemotherapy were reviewed to determine response to therapy, treatment outcome and possible prognostic indicators. All cats were treated with megavoltage radiation therapy to a total dose ranging from 22 to 48 Gy (median dose=42 Gy). All cats were prescribed at least 6 months of multiagent chemotherapy. The median progression-free interval for all cats was 945 days (31 months). Two cats did not achieve clinical remission. Of 17 cats evaluable for relapse, 10 (58.8?) were progression free during the entire follow-up period. Four cats (23.5?) suffered local recurrence, while three (17.6?) experienced distant relapse. The median survival time was 955 days (31.4 months). The only variable found to have a significant negative impact on survival was destruction of the cribriform plate before therapy (P=0.002). The long progression free and survival times reported here indicate that cats with stage I nasal lymphoma treated with aggressive local and systemic therapy can have a favorable outcome when compared with other anatomic forms of lymphoma. Despite strong clinical responses to the multimodality therapy used, the fact that three (17.6?) cats relapsed distantly supports the recommendation that treatment with radiation therapy alone is insufficient until further prospective studies can be performed.",
keywords = "Feline, Nasal lymphosarcoma, Treatment",
author = "Gabriella Sfiligoi and Theon, {Alain P} and Kent, {Michael S}",
year = "2007",
month = "7",
doi = "10.1111/j.1740-8261.2007.00262.x",
language = "English (US)",
volume = "48",
pages = "388--393",
journal = "Veterinary Radiology and Ultrasound",
issn = "1058-8183",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Response of nineteen cats with nasal lymphoma to radiation therapy and chemotherapy

AU - Sfiligoi, Gabriella

AU - Theon, Alain P

AU - Kent, Michael S

PY - 2007/7

Y1 - 2007/7

N2 - The records of 19 cats treated for stage I nasal lymphoma with radiation therapy and chemotherapy were reviewed to determine response to therapy, treatment outcome and possible prognostic indicators. All cats were treated with megavoltage radiation therapy to a total dose ranging from 22 to 48 Gy (median dose=42 Gy). All cats were prescribed at least 6 months of multiagent chemotherapy. The median progression-free interval for all cats was 945 days (31 months). Two cats did not achieve clinical remission. Of 17 cats evaluable for relapse, 10 (58.8?) were progression free during the entire follow-up period. Four cats (23.5?) suffered local recurrence, while three (17.6?) experienced distant relapse. The median survival time was 955 days (31.4 months). The only variable found to have a significant negative impact on survival was destruction of the cribriform plate before therapy (P=0.002). The long progression free and survival times reported here indicate that cats with stage I nasal lymphoma treated with aggressive local and systemic therapy can have a favorable outcome when compared with other anatomic forms of lymphoma. Despite strong clinical responses to the multimodality therapy used, the fact that three (17.6?) cats relapsed distantly supports the recommendation that treatment with radiation therapy alone is insufficient until further prospective studies can be performed.

AB - The records of 19 cats treated for stage I nasal lymphoma with radiation therapy and chemotherapy were reviewed to determine response to therapy, treatment outcome and possible prognostic indicators. All cats were treated with megavoltage radiation therapy to a total dose ranging from 22 to 48 Gy (median dose=42 Gy). All cats were prescribed at least 6 months of multiagent chemotherapy. The median progression-free interval for all cats was 945 days (31 months). Two cats did not achieve clinical remission. Of 17 cats evaluable for relapse, 10 (58.8?) were progression free during the entire follow-up period. Four cats (23.5?) suffered local recurrence, while three (17.6?) experienced distant relapse. The median survival time was 955 days (31.4 months). The only variable found to have a significant negative impact on survival was destruction of the cribriform plate before therapy (P=0.002). The long progression free and survival times reported here indicate that cats with stage I nasal lymphoma treated with aggressive local and systemic therapy can have a favorable outcome when compared with other anatomic forms of lymphoma. Despite strong clinical responses to the multimodality therapy used, the fact that three (17.6?) cats relapsed distantly supports the recommendation that treatment with radiation therapy alone is insufficient until further prospective studies can be performed.

KW - Feline

KW - Nasal lymphosarcoma

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=34547370379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547370379&partnerID=8YFLogxK

U2 - 10.1111/j.1740-8261.2007.00262.x

DO - 10.1111/j.1740-8261.2007.00262.x

M3 - Article

C2 - 17691642

AN - SCOPUS:34547370379

VL - 48

SP - 388

EP - 393

JO - Veterinary Radiology and Ultrasound

JF - Veterinary Radiology and Ultrasound

SN - 1058-8183

IS - 4

ER -